kella viiene data:
February Pending Home Sales +2.1% vs 0.3% Briefing.com consensus
Bloombergi andmetel on Goldman täna oluliselt langetamas oma Q1 SKT prognoosi. Kui varem oodati kvartaalselt 3.5%list kasvu (annualiseeritud), siis sellist numbrit me suure tõeänosusega ei näe. Goldmani prognoosi mõjutas tänane tarbijakulutuste raport (Goldman ootas kulutuste üle 3%list qoq kasvu).
Philly Fed'i president, Charles Plosser, andis reedel kõne, mida finantsmeedia kanalid täna mitte mainimata ei saa jätta. Keskpankuri kõne saab lugeda siit. Tähtsaim osa kõnest asub aga viimasel lehel (allolev tabel). Võttes arvesse, et tänavu on toimumas veel 6 FOMC kohtumist, siis Plosseri hinnangul võib Fed Funds Rate olla aasta lõpuks 1.75%. Plosser on avaldanud ka arvamust, et QE2 peaks lõpetama enne suve.
The Fed purchased $6.75 bln of 2015-2016 maturities through Permanent Open Market Operations as dealers looked to put back $23.75 bln
NVDA-l võttis täna liikumasaamine natuke aega. Aktsia avanes $19,07 pealt ning tuli peale avanemist natuke alla $18,90 kanti ja on sealt turu toel ülespoole liikunud, käies ära ka $19,60 all. Hetkel kaupleb NVDA $19,43 kandis ehk 4,3% plusspoolel.
LLoyds said to hire JPMorgan, Citigroup to sell 600 branches
$35 bln 2-yr Note Auction Results: 0.789%; Bid/Cover 3.16x (Prior 3.03x, 10-auction avg 3.40x); Indirect Bidders 33% (Prior 31.3%, 10-auction avg 33.8%)
Tesla Motors (TSLA) trades to HoD; Hearing move attributed to takeover chatter
DNDN osas otsust veel ei ole?
Medicare may cover Dendreon drug. Provenge, Dendreon's (DNDN) prostate cancer treatment, should be covered by Medicare for use in older men, regulators proposed yesterday. The decision is critical for Dendreon as 75% of the men approved for Provenge are eligible for Medicare. Analysts estimate that the coverage will help Provenge generate $2.3B in sales in 2014. A final verdict will be issued June 30. Shares are +3.7% in pre-market trading (7:00 ET).
Kas viimane otsustamise aeg hoopis 30 juuni?
Medicare may cover Dendreon drug. Provenge, Dendreon's (DNDN) prostate cancer treatment, should be covered by Medicare for use in older men, regulators proposed yesterday. The decision is critical for Dendreon as 75% of the men approved for Provenge are eligible for Medicare. Analysts estimate that the coverage will help Provenge generate $2.3B in sales in 2014. A final verdict will be issued June 30. Shares are +3.7% in pre-market trading (7:00 ET).
Kas viimane otsustamise aeg hoopis 30 juuni?
to rinx: Just, ametlik otsus teatatakse 30. juunil, aga nö eelotsus on Provenge katmise poolt.